Key clinical point: Use of intravenous glycopyrronium bromide had no significant impact on radiation toxicity in prostate cancer patients treated with the prostate-specific membrane antigen ¹⁷⁷Lu/²²⁵Ac-PSMA.

Major finding: The average PSMA uptake in the parotid glands in the intervention group vs. control were 5.72 and 5.57; average PSMA uptake in the submandibular glands for the two groups was 5.89 and 6.25, respectively.

Study details: The data come from 10 prostate cancer patients who underwent PET scans with and without intravenous injections of 0.2 mg glycopyrronium bromide (GPB) to potentially reduce the impact of radiation on the salivary glands.

Disclosures: The study was supported by the Dutch Cancer Society KWF. The researchers had no financial conflicts to disclose.